Morepen Laboratories Limited has informed the Exchange regarding Appointment of Harvinder & Associates, Internal Auditors as Other of the company w.e.f. April 01, 2025.
MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Morepen Laboratories' board met on May 12, 2025 and approved several items. The company signed an addendum to its Business Transfer Agreement with subsidiary Morepen Medipath, shifting the appointed date for the medical devices business hive-off from February 1, 2025 to April 1, 2025. Audited FY25 results showed consolidated total income rising to Rs. 1,829.94 crore (from Rs. 1,704.40 crore) and net profit after minority interest at Rs. 118.02 crore (from Rs. 96.16 crore), a 22.7% jump. Standalone net profit slipped to Rs. 101.58 crore from Rs. 110.94 crore. The board recommended a final dividend of Rs. 0.20 per share (on Rs. 2 face value) for FY25. Through its subsidiary Morepen Medipath, the company plans to set up a wholly owned subsidiary in Dubai to expand medical device B2B and B2C business. Vijender Sharma & Co. was named cost auditor and Harvinder & Associates was appointed as internal auditor for FY26.
Shareholders get a small Rs. 0.20 per share dividend, while consolidated earnings show healthy growth driven by subsidiaries. The medical devices hive-off to Morepen Medipath and the planned Dubai expansion signal a sharper focus on the medical device business, which could reshape the company's segment mix going forward.